Five drugs met these criteria: Topiramate in ATC N03AX (treating epilepsy, targeting GABRA4), Desipramine, Imipramine, and Nortriptyline in ATC N06AA (treating depression and anxiety, targeting BDNF) and Methylphenidate in ATC N06BA (treating ADHD, targeting DRD2). This evidence concerns the gene GABRA4 and depressive symptom measurement.